WIN378

Phase 2Small molecule

WWindward Bio

WIN378 is one of 22 small molecule programs targeting Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaActive, not recruiting

COPD (chronic Obstructive Pulmonary Disease)Recruiting

AsthmaPhase 2

Active, not recruiting

COPD (chronic Obstructive Pulmonary Disease)Phase 2

Recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Cinqair

Teva

Preclinical

13 2

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 3

Arcoxia

Symbicort

6 5

Atrovent

Boehringer Ingelheim

Preclinical

2 6

Aciphex

Akero Therapeutics

Preclinical

2 7

WIN378

WWindward Bio

Phase 2

1 8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

1 9

Ozone

TTanta University

Preclinical

1 10

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Asthma

NCT07120503

Q1 2028

Phase 2Recruiting

COPD (chronic Obstructive Pulmonary Disease)

NCT07646587

Clinical

Trials by Indication[1]

Asthma1 trial

Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

Recruiting·WWindward Bio·Phase 2·NCT07120503·136 enrolled

COPD (Chronic Obstructive Pulmonary Disease)1 trial

A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of WIN378 in Participants With Moderate - Severe Chronic Obstructive Pulmonary Disease

Recruiting·WWindward Bio·Phase 2·NCT07646587·105 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for WIN378. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — WIN378 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for WIN378. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Windward Bio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWindward Bio

WIN378

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Trials by Indication[1]

Asthma1 trial

COPD (Chronic Obstructive Pulmonary Disease)1 trial

References

Drug Info

Quick Facts

Related News